Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Brief: New Triple-Combination Therapies Help Boost Lackluster Inhalation Devices Market

Executive Summary

The inhalation devices market will reach $12bn by 2023, driven by the rising prevalence of asthma and COPD worldwide. GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim dominate worldwide sales of inhalation products for asthma and COPD, and are facing generic competition. Generics developers and major pharma players are trying to set themselves apart with better drug-delivery devices. 

You may also be interested in...



Market Snapshot: Ventilators & Pulmonary Function Assessment Products Market Sees Moderate Growth

The global market for ventilators and pulmonary function assessment products is expected to reach $1.7bn by 2022, driven in large part by rising incidences of pulmonary diseases in the elderly population. The larger market segment of diagnostics spirometry products will grow at a faster rate than the smaller pulmonary function testing and disposable products market, driven by an emphasis of disease prevention via early diagnosis in outpatient and alternate care settings. Check out our infographic on the market.

AstraZeneca Enlists Owlstone Medical To Identify Asthma And COPD Biomarkers

Owlstone Medical has signed another major collaboration agreement with a big pharma company to use its breath biopsy services. The Cambridge, UK company is partnering with AstraZeneca to to identify novel breath biomarkers for asthma and COPD.

SNAPSHOT: Inhalation Drug Delivery Devices Growing Slowly But Surely

The rise in respiratory problems such as asthma and chronic obstructive pulmonary disorder will buoy growth in the $11.7bn inhalation drug delivery device market. While global sales increase of these devices will be modest, some geographic regions will see faster pace growth than others, according to a report by Meddevicetracker.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel